Patents by Inventor Véronique DEHLINGER

Véronique DEHLINGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY
    Publication number: 20230250070
    Abstract: The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, IL-1 beta and/or IL-18 levels.
    Type: Application
    Filed: June 18, 2021
    Publication date: August 10, 2023
    Applicant: AC IMMUNE SA
    Inventors: Emanuele GABELLIERI, Jérôme MOLETTE, Véronique DEHLINGER
  • 3-indazolyl-4-pyridylisothiazoles
    Patent number: 7932274
    Abstract: The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: April 26, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Adam Michael Fivush, Sean Patrick Hollinshead, Benjamin Paul Vokits
  • 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
    Patent number: 7868014
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 11, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum
  • 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES
    Publication number: 20090253750
    Abstract: The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.
    Type: Application
    Filed: March 18, 2009
    Publication date: October 8, 2009
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Adam Michael Fivush, Sean Patrick Hollinshead, Benjamin Paul Vokits
  • 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists
    Publication number: 20080300266
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 13, 2005
    Publication date: December 4, 2008
    Applicant: Eli Lilly And Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum